MIPS is launching a new seminar series, IMAGinING THE FUTURE, aimed at catalyzing interdisciplinary discussions in all areas of medicine and disease.
This seminar series is open and free to everyone in the Stanford community, as well as anyone from the surrounding community, universities, companies, or institutions. Register here for the January 31 seminar.
Douglas Lowy, M.D., is the Deputy Director of the National Cancer Institute (NCI) of the National Institutes of Health (NIH). Lowy previously served as NCI’s deputy director, helping lead NCI’s key scientific initiatives since 2010.
A cancer researcher for more than 40 years, Lowy received the National Medal of Technology and Innovation from President Obama in 2014 for his research that led to the development of the human papillomavirus (HPV) vaccine. As chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI, Lowy’s research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. His laboratory, in close collaboration with John T. Schiller, Ph.D., was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three U.S. Food and Drug Administration-approved HPV vaccines.
Lowy is a member of the National Academy of Sciences (NAS), as well as the Institute of Medicine of the NAS. For their pioneering work, Lowy and Schiller have received numerous honors in addition to the National Medal, including the 2011 Albert B. Sabin Gold Medal Award and the Federal Employee of the Year Award in 2007 from the Partnership for Public Service.
Lowy received his medical degree from New York University School of Medicine, New York City, and trained in internal medicine at Stanford University, California, and dermatology at Yale University, New Haven, Connecticut.